News

FSHD is one of the most common forms of muscular dystrophy and genetic hereditary diseases seen in skeletal muscle. It is estimated that it affects 7 in 100,000

Boehringer Ingelheim Vetmedica has secured the licensing rights for the technology platform Artilysin®. The company is hopeful to receive significant momentum and solutions from this new substance class

The patient was enrolled by one of the trial’s lead principal investigators at a Pituitary Center from a prestigious institution in Baltimore, Maryland. "The enrollment of the first

Designed by The Arthritis Society, the unique pain management program will be rolled out in participating pharmacies in Autumn 2014 under the diem™ therapeutic brand. Pharmacists that have

The actual manufacturing of the company’s Emesyl® product is on schedule to begin August 18, 2014. We are pleased to be able to make these dates available to

SGN-CD70A is a new antibody-drug conjugate (ADC) targeted to CD70 using the company’s new ADC technology. The open-label, multi-center, dose-escalation Phase I trial is designed to evaluate the

As part of the deal, Sigma-Tau will be responsible for the sales, marketing and distribution of Colief in the US. Sigma-Tau has planned a re-launch of Colief at

Diprivan is an intravenous sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Fresenius Kabi USA president and CEO John Ducker said the Diprivan

The NDS is based on results from two pivotal Phase III trials, REFINE-1 and REFINE-2, which were reported in late 2013. In these trials, the majority of ATX-101